| __timestamp | AstraZeneca PLC | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 122000 |
| Thursday, January 1, 2015 | 4646000000 | 1896000 |
| Friday, January 1, 2016 | 4126000000 | 2699000 |
| Sunday, January 1, 2017 | 4318000000 | 1702000 |
| Monday, January 1, 2018 | 4936000000 | 471000 |
| Tuesday, January 1, 2019 | 4921000000 | 4101000 |
| Wednesday, January 1, 2020 | 5299000000 | 1676000 |
| Friday, January 1, 2021 | 12437000000 | 7264000 |
| Saturday, January 1, 2022 | 12391000000 | 6594000 |
| Sunday, January 1, 2023 | 8040000000 | 4661000 |
| Monday, January 1, 2024 | 10207000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This chart offers a decade-long comparison of the cost of revenue for AstraZeneca PLC and BioCryst Pharmaceuticals, Inc., from 2014 to 2023. AstraZeneca, a global leader, consistently shows a higher cost of revenue, peaking in 2021 with a staggering 12.4 billion USD, reflecting its expansive operations and market reach. In contrast, BioCryst Pharmaceuticals, a smaller player, had a peak cost of revenue of just 7.3 million USD in the same year, highlighting its niche focus. Over the years, AstraZeneca's cost of revenue has grown by approximately 38%, while BioCryst's has seen a more volatile trajectory. This data underscores the scale and operational differences between a pharmaceutical giant and a specialized biotech firm, offering insights into their financial strategies and market positioning.
Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc
Analyzing Cost of Revenue: AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Xencor, Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Amneal Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for BioCryst Pharmaceuticals, Inc. and Xencor, Inc.